Works matching Pharmacodynamics

Results: 5000
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes

    Published in:
    Diabetes, Obesity & Metabolism, 2013, v. 15, n. 3, p. 241, doi. 10.1111/dom.12016
    By:
    • Korsatko, S.;
    • Glettler, K.;
    • Olsen, K. J.;
    • Wutte, A.;
    • Bock, G.;
    • Koehler, G.;
    • Mader, J. K.;
    • Semlitsch, B.;
    • Pieber, T. R.
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41

    Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha- 2b and gamma in healthy male volunteers.

    Published in:
    BMC Pharmacology & Toxicology, 2016, v. 17, p. 1, doi. 10.1186/s40360-016-0103-8
    By:
    • García-García, Idrian;
    • Hernández-González, Ignacio;
    • Díaz-Machado, Alina;
    • González-Delgado, Carlos A.;
    • Pérez-Rodríguez, Sonia;
    • García-Vega, Yanelda;
    • Campos-Mojena, Rosario;
    • Tuero-Iglesias, Ángela D.;
    • Valenzuela-Silva, Carmen M.;
    • Cruz-Ramírez, Alieski;
    • Martín-Trujillo, Alis;
    • Santana-Milián, Héctor;
    • López-Saura, Pedro A.;
    • Bello-Rivero, Iraldo
    Publication type:
    Article
    42
    43
    44
    45

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M<sub>3</sub> Receptor‐Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers.

    Published in:
    Clinical Pharmacology in Drug Development, 2024, v. 13, n. 10, p. 1130, doi. 10.1002/cpdd.1460
    By:
    • Takusagawa, Shin;
    • Treijtel, Nicoline;
    • Saito, Masako;
    • Michon, Ingrid;
    • Miyatake, Daisuke;
    • Osaki, Fumio;
    • Guro, Sayuri;
    • Fadini, Tomasso;
    • Sekino, Hisakuni;
    • Aarden‐Bakker, Marlous;
    • Kuroishi, Kentaro;
    • van Till, Jan Willem Olivier;
    • Groenendaal‐van de Meent, Dorien;
    • de Vries, Michiel
    Publication type:
    Article
    46
    47
    48
    49
    50

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose).

    Published in:
    Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 202, doi. 10.1002/cpdd.1162
    By:
    • Parmar, Deven V.;
    • Kansagra, Kevinkumar A.;
    • Momin, Taufik;
    • Patel, Hardik B.;
    • Jansari, Gaurav A.;
    • Bhavsar, Jay;
    • Shah, Chintan;
    • Patel, Jayesh M.;
    • Ghoghari, Ashok;
    • Barot, Ajay;
    • Sharma, Bhavesh;
    • Viswanathan, Kasinath;
    • Patel, Harilal V.;
    • Jain, Mukul R.
    Publication type:
    Article